

The impact of SARS-CoV-2 vaccines on antibody responses in the general population in the United Kingdom: Supplementary material

Supplementary tables

	No evidence of prior infection			Evidence of prior infection			p value
	One dose AZ (N=23368)	One dose Pf (N=14894)	Two doses Pf(N=1869)	One dose AZ (N=3767)	One dose Pf (N=2067)	Total (N=45965)	
Duration between two doses [Median (IQR)]	31 (21-47)						
Age							< 0.001
Median	63	66	70	61	62	64	
IQR	55, 70	54, 73	53, 80	52, 68	50, 70	54, 71	
Sex							< 0.001
Female	12510 (53.5%)	8497 (57.0%)	1153 (61.7%)	2034 (54.0%)	1136 (55.0%)	25330 (55.1%)	
Male	10858 (46.5%)	6397 (43.0%)	716 (38.3%)	1733 (46.0%)	931 (45.0%)	20635 (44.9%)	
Ethnicity							< 0.001
Non-white	1110 (4.8%)	817 (5.5%)	118 (6.3%)	241 (6.4%)	148 (7.2%)	2434 (5.3%)	
White	22258 (95.2%)	14077 (94.5%)	1751 (93.7%)	3526 (93.6%)	1919 (92.8%)	43531 (94.7%)	
Household size							< 0.001
1	5019 (21.5%)	3302 (22.2%)	501 (26.8%)	721 (19.1%)	395 (19.1%)	9938 (21.6%)	
2	12990 (55.6%)	8260 (55.5%)	985 (52.7%)	1916 (50.9%)	1072 (51.9%)	25223 (54.9%)	
3	2863 (12.3%)	1688 (11.3%)	168 (9.0%)	545 (14.5%)	312 (15.1%)	5576 (12.1%)	
4	1797 (7.7%)	1130 (7.6%)	145 (7.8%)	403 (10.7%)	202 (9.8%)	3677 (8.0%)	
5+	699 (3.0%)	514 (3.5%)	70 (3.7%)	182 (4.8%)	86 (4.2%)	1551 (3.4%)	
Deprivation percentile							< 0.001
Median	63	64	64	60	57	63	
IQR	40, 82	40, 83	38, 83	35, 81	32, 79	39, 82	
Report working in patient facing healthcare							< 0.001
No	22860 (97.8%)	13430 (90.2%)	1466 (78.4%)	3636 (96.5%)	1828 (88.4%)	43220 (94.0%)	
Yes	508 (2.2%)	1464 (9.8%)	403 (21.6%)	131 (3.5%)	239 (11.6%)	2745 (6.0%)	
Report working in person facing social care							< 0.001
No	23149 (99.1%)	14548 (97.7%)	1800 (96.3%)	3717 (98.7%)	2014 (97.4%)	45228 (98.4%)	
Yes	219 (0.9%)	346 (2.3%)	69 (3.7%)	50 (1.3%)	53 (2.6%)	737 (1.6%)	
Report working in a care home (any role)							< 0.001
No	23195 (99.3%)	14551 (97.7%)	1778 (95.1%)	3701 (98.2%)	2011 (97.3%)	45236 (98.4%)	
Yes	173 (0.7%)	343 (2.3%)	91 (4.9%)	66 (1.8%)	56 (2.7%)	729 (1.6%)	
Report having long-term health condition							< 0.001
No	15774 (67.5%)	9597 (64.4%)	1217 (65.1%)	2645 (70.2%)	1398 (67.6%)	30631 (66.6%)	
Yes	7594 (32.5%)	5297 (35.6%)	652 (34.9%)	1122 (29.8%)	669 (32.4%)	15334 (33.4%)	

Table S1. Participants' characteristics by cohort. AZ: Oxford-AstraZeneca vaccine. Pf: Pfizer-BioNTech vaccine. Note: higher deprivation percentile means living in a less deprived area.

Time (days)	Age	No prior infection			Prior infection	
		AZ one dose	Pfizer one dose	Pfizer two doses	AZ one dose	Pfizer one dose
Logistic model		Predicted probability of anti-spike IgG positivity (95%CI)				
0	20	1 (0-3)	0 (0-1)	5 (1-16)	90 (82-95)	94 (88-97)
0	40	1 (0-1)	0 (0-1)	2 (1-5)	85 (80-88)	89 (84-92)
0	60	0 (0-0)	0 (0-0)	1 (1-2)	78 (75-82)	81 (77-84)
0	80	0 (0-0)	0 (0-0)	0 (0-1)	70 (61-78)	69 (59-77)
7	20	9 (4-20)	29 (17-45)	60 (34-81)	91 (83-96)	97 (94-99)
7	40	6 (4-10)	13 (9-18)	36 (23-52)	88 (83-91)	94 (90-96)
7	60	5 (4-6)	6 (4-8)	18 (12-25)	82 (78-85)	87 (83-90)
7	80	2 (1-4)	3 (2-5)	8 (4-14)	74 (66-81)	73 (64-81)
14	20	79 (62-90)	97 (92-99)	95 (87-98)	93 (86-97)	99 (97-100)
14	40	63 (55-71)	95 (92-97)	89 (80-94)	92 (89-94)	97 (95-99)
14	60	49 (44-53)	89 (86-91)	78 (70-83)	89 (87-92)	95 (93-96)
14	80	20 (14-28)	66 (59-72)	60 (49-70)	83 (76-88)	90 (84-93)
21	20	90 (77-96)	98 (94-99)	98 (93-99)	96 (89-98)	99 (97-100)
21	40	85 (78-90)	96 (94-98)	96 (91-98)	95 (92-97)	99 (97-99)
21	60	81 (77-84)	93 (91-95)	91 (87-94)	95 (93-96)	98 (97-98)
21	80	60 (52-68)	81 (75-85)	84 (77-89)	90 (85-93)	96 (93-98)
28	20	90 (74-96)	97 (93-99)	97 (89-99)	97 (92-99)	99 (97-100)
28	40	84 (76-89)	95 (92-97)	95 (90-98)	97 (94-98)	99 (98-100)
28	60	79 (75-83)	91 (89-93)	93 (89-95)	96 (95-97)	98 (97-99)
28	80	74 (66-80)	85 (80-89)	89 (84-93)	94 (90-96)	98 (95-99)
35	20	94 (79-99)	98 (95-99)	93 (83-98)	99 (93-100)	99 (97-100)
35	40	86 (78-91)	96 (93-97)	94 (88-97)	98 (95-99)	99 (98-100)
35	60	80 (75-84)	91 (89-93)	94 (91-96)	97 (96-98)	98 (97-99)
35	80	74 (67-80)	81 (76-85)	94 (90-97)	95 (92-97)	97 (95-99)
42	20	92 (72-98)	98 (94-99)	95 (86-98)	99 (93-100)	100 (98-100)
42	40	84 (75-90)	96 (93-97)	94 (88-97)	99 (95-100)	99 (98-100)
42	60	79 (73-84)	91 (88-93)	93 (89-95)	97 (95-99)	98 (97-99)
42	80	75 (67-81)	82 (77-86)	91 (85-95)	96 (91-98)	96 (93-98)
49	20	80 (39-96)	98 (94-99)	95 (87-98)	-	100 (98-100)
49	40	84 (71-92)	95 (92-97)	94 (89-97)	-	100 (97-100)
49	60	78 (67-86)	89 (85-92)	93 (89-95)	-	98 (96-99)
49	80	78 (67-86)	79 (74-84)	91 (85-94)	-	92 (86-96)
Linear model		Predicted anti-spike IgG levels in mAb units (95%CI)				
0	20	7 (5-9)	4 (3-6)	5 (3-8)	123 (82-185)	139 (90-216)
0	40	6 (5-7)	5 (5-6)	5 (4-7)	96 (78-119)	126 (102-156)
0	60	5 (5-6)	5 (4-5)	6 (5-7)	94 (81-108)	98 (83-115)
0	80	4 (4-5)	5 (4-5)	5 (4-6)	69 (53-90)	71 (55-92)
7	20	9 (7-12)	14 (11-18)	30 (17-52)	167 (111-251)	220 (141-342)
7	40	7 (7-8)	10 (9-11)	17 (13-22)	169 (136-210)	202 (162-250)
7	60	6 (6-6)	7 (7-8)	10 (8-12)	152 (132-176)	138 (117-163)
7	80	5 (4-5)	5 (5-5)	6 (5-8)	88 (67-117)	85 (66-108)

14	20	90 (71-115)	293 (228-375)	182 (110-301)	242 (155-376)	307 (204-464)
14	40	50 (45-56)	201 (181-225)	151 (117-196)	306 (243-386)	301 (244-371)
14	60	38 (36-40)	127 (119-137)	105 (86-128)	248 (214-287)	254 (217-298)
14	80	16 (15-19)	61 (56-67)	48 (39-58)	126 (96-166)	143 (113-181)
21	20	197 (152-257)	325 (258-409)	287 (173-478)	318 (197-514)	363 (243-542)
21	40	113 (100-127)	250 (225-277)	219 (171-280)	381 (299-485)	398 (324-489)
21	60	91 (85-97)	173 (162-185)	166 (136-202)	312 (267-365)	361 (307-424)
21	80	52 (47-58)	101 (93-110)	123 (103-147)	182 (141-236)	223 (174-286)
28	20	127 (94-171)	334 (266-420)	259 (153-440)	389 (237-639)	380 (245-591)
28	40	113 (99-129)	236 (214-261)	232 (179-301)	369 (286-477)	402 (324-497)
28	60	94 (87-100)	163 (153-175)	192 (158-232)	347 (291-413)	385 (328-452)
28	80	73 (65-81)	113 (104-123)	163 (136-196)	224 (173-290)	281 (221-356)
35	20	192 (135-274)	359 (278-464)	250 (157-400)	485 (274-860)	401 (250-644)
35	40	125 (108-144)	216 (193-242)	196 (157-246)	356 (267-476)	404 (321-508)
35	60	92 (85-100)	159 (148-171)	160 (133-193)	345 (283-420)	361 (305-429)
35	80	71 (64-79)	108 (99-117)	212 (180-251)	218 (165-288)	295 (234-372)
42	20	188 (123-288)	287 (221-373)	344 (215-551)	622 (251-1542)	424 (262-685)
42	40	93 (80-109)	202 (178-229)	244 (192-310)	412 (273-621)	411 (320-527)
42	60	86 (78-95)	146 (134-159)	191 (159-229)	335 (259-433)	353 (292-426)
42	80	74 (66-83)	94 (86-104)	175 (145-211)	200 (146-275)	280 (222-353)
49	20	107 (59-196)	269 (206-351)	382 (241-608)	-	450 (260-777)
49	40	108 (85-139)	177 (155-202)	264 (210-332)	-	441 (336-579)
49	60	79 (66-94)	117 (106-129)	218 (181-263)	-	385 (312-475)
49	80	73 (62-87)	81 (74-89)	220 (184-262)	-	273 (212-351)

Table S2. Predicted probability of anti-spike IgG seropositivity and anti-spike IgG levels (in mAb units) with 95% confidence interval (CI) according to age, vaccine type and dose, and prior infection status by weeks after vaccination. AZ: Oxford-AstraZeneca vaccine. Pf: Pfizer-BioNTech vaccine.

	Oxford-AstraZeneca					Pfizer-BioNTech				
	Class 1 (N=867)	Class 2 (N=7097)	Class 3 (N=13163)	Class 4 (N=1297)	p value	Class 1 (N=547)	Class 2 (N=8951)	Class 3 (N=3876)	Class 4 (N=720)	p value
Percentage	3.9%	31.6%	58.7%	5.8%		3.9%	63.5%	27.5%	5.1%	
Age					< 0.001					< 0.001
Median	58	60	64	68		64	62	72	71	
IQR	50, 66	48, 68	57, 70	60, 73		50, 73	49, 70	66, 77	62, 78	
Age group					< 0.001					< 0.001
16-34	73 (8.4%)	709 (10.0%)	167 (1.3%)	22 (1.7%)		63 (11.5%)	760 (8.5%)	12 (0.3%)	26 (3.6%)	
35-54	274 (31.6%)	1863 (26.3%)	2412 (18.3%)	165 (12.7%)		119 (21.8%)	2240 (25.0%)	231 (6.0%)	76 (10.6%)	
55-74	461 (53.2%)	4119 (58.0%)	9185 (69.8%)	862 (66.5%)		250 (45.7%)	4863 (54.3%)	2209 (57.0%)	354 (49.2%)	
>75	59 (6.8%)	406 (5.7%)	1399 (10.6%)	248 (19.1%)		115 (21.0%)	1088 (12.2%)	1424 (36.7%)	264 (36.7%)	
Sex					< 0.001					< 0.001
Female	453 (52.2%)	4467 (62.9%)	6505 (49.4%)	600 (46.3%)		305 (55.8%)	5577 (62.3%)	1721 (44.4%)	364 (50.6%)	
Male	414 (47.8%)	2630 (37.1%)	6658 (50.6%)	697 (53.7%)		242 (44.2%)	3374 (37.7%)	2155 (55.6%)	356 (49.4%)	
Report working in patient facing healthcare					< 0.001					< 0.001
No	834 (96.2%)	6902 (97.3%)	12966 (98.5%)	1276 (98.4%)		475 (86.8%)	7976 (89.1%)	3791 (97.8%)	692 (96.1%)	
Yes	33 (3.8%)	195 (2.7%)	197 (1.5%)	21 (1.6%)		72 (13.2%)	975 (10.9%)	85 (2.2%)	28 (3.9%)	
Report having long-term health condition					< 0.001					< 0.001
No	592 (68.3%)	5104 (71.9%)	8859 (67.3%)	636 (49.0%)		355 (64.9%)	6219 (69.5%)	2096 (54.1%)	344 (47.8%)	
Yes	275 (31.7%)	1993 (28.1%)	4304 (32.7%)	661 (51.0%)		192 (35.1%)	2732 (30.5%)	1780 (45.9%)	376 (52.2%)	
Membership probability (%)					< 0.001					< 0.001
Median	98	82	71	99		94	89	86	100	
IQR	78, 100	61, 97	54, 92	84, 100		75, 100	74, 98	64, 97	91, 100	

Table S3. Characteristics of classes identified from latent class mixed models for single dose Oxford-AstraZeneca and Pfizer-BioNTech vaccines in those without evidence of prior infection. Class 1='plausibly previously infected' group, 2='high response' group, 3='medium response' group, 4='low response group'.

Supplementary figures




Figure S1. Predicted probability of anti-spike IgG positivity by time from first vaccination and age, according to vaccine type and prior infection status (full model). Predictions shown for specific ages in **Figure 1**. Observed data in **Supplementary Figures S3-S7**.




Figure S2. Predicted probability of anti-spike IgG positivity by time from first vaccination for ages 20, 40, 60, and 80 years (full models shown in **Figure S1**, plotted by vaccine in **Figure 1**). Line colour indicates different vaccine type and prior infection status. Data identical to **Figure 1**, but Figure 1 panels represent age rather than vaccine type as here.




Figure S3. Percentage (95% CI) anti-spike IgG positive by days after first vaccination in participants receiving a single dose of Oxford-AstraZeneca vaccine and without evidence of prior infection. Results were divided into four age groups: 16-34, 35-54, 55-74, and >75 years.



Figure S4. Percentage (95% CI) anti-spike IgG positives by days after first vaccination in participants receiving a single dose of Oxford-AstraZeneca vaccine and with evidence of prior infection. Results were divided into four age groups: 16-34, 35-54, 55-74, and >75 years.




Figure S5. Percentage (95% CI) anti-spike IgG positives by days after first vaccination in people receiving a single dose of Pfizer-BioNTech vaccine and without evidence of prior infection. Results were divided into four age groups: 16-34, 35-54, 55-74, and >75 years.




Figure S6. Percentage (95% CI) anti-spike IgG positives by days after first vaccination in people receiving a single dose of Pfizer-BioNTech vaccine and with evidence of prior infection. Results were divided into four age groups: 16-34, 35-54, 55-74, and >75 years.




Figure S7. Percentage (95% CI) anti-spike IgG positives by days after first vaccination in people receiving two doses of Pfizer-BioNTech vaccine and without evidence of prior infection. Results were divided into four age groups: 16-34, 35-54, 55-74, and >75 years.




Figure S8. Predicted anti-spike IgG levels (in mAb units) by time from first vaccination and age, according to vaccine type and prior infection status (full model). Predictions shown for specific ages in **Figure 3**.




Figure S9. Age distribution by classes identified from latent class mixed models for single dose Oxford-AstraZeneca and Pfizer-BioNTech vaccines. 1='plausibly previously infected' group, 2='high response' group, 3='medium response' group, 4='low response group'. Same area for each violin, see Table S3 for numbers in each group.